United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
316.95
-3.42 (-1.07%)
May 30, 2025, 2:37 PM - Market open
United Therapeutics Stock Forecast
Stock Price Forecast
According to 12 professional analysts, the 12-month price target for United Therapeutics stock ranges from a low of $302 to a high of $600. The average analyst price target of $392 forecasts a 23.68% increase in the stock price over the next year.
Price Target: $392.00 (+23.68%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for United Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 6 | 5 | 3 | 3 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 4 | 4 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 14 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $425 | Strong Buy | Reiterates | $425 | +34.09% | May 5, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $355 → $350 | Buy | Maintains | $355 → $350 | +10.43% | May 1, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $346 → $348 | Hold | Maintains | $346 → $348 | +9.80% | May 1, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $395 → $314 | Buy → Hold | Downgrades | $395 → $314 | -0.93% | Apr 25, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $357 → $355 | Buy | Maintains | $357 → $355 | +12.01% | Apr 21, 2025 |
Financial Forecast
Revenue This Year
3.29B
from 2.88B
Increased by 14.37%
Revenue Next Year
3.49B
from 3.29B
Increased by 6.05%
EPS This Year
28.21
from 24.64
Increased by 14.49%
EPS Next Year
29.01
from 28.21
Increased by 2.84%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.5B | 3.8B | 4.6B | ||
| Avg | 3.3B | 3.5B | 3.6B | ||
| Low | 3.0B | 3.0B | 2.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 23.1% | 14.1% | 31.6% | ||
| Avg | 14.4% | 6.0% | 3.6% | ||
| Low | 4.5% | -8.8% | -16.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 31.46 | 32.97 | 41.06 | ||
| Avg | 28.21 | 29.01 | 29.02 | ||
| Low | 24.15 | 22.30 | 18.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 27.7% | 16.9% | 41.5% | ||
| Avg | 14.5% | 2.8% | 0.0% | ||
| Low | -2.0% | -21.0% | -37.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.